

## **1<sup>st</sup> National North of England Cancer Associated Thrombosis Conference (NEONC CAT)**

**10<sup>th</sup> November 2023, Lazaat Hotel, Cottingham, UK**

### **Speaker Biographies**

#### **Isabelle Mahé, Professor Internal Medicine, Université Paris Cité**



A specialist in cardiovascular disease by training, Isabelle Mahé is Professor of Internal Medicine at Université Paris Cité. She is Head of the Internal Medicine Department at a teaching hospital (Louis Mourier, Assistance Publique Hôpitaux de Paris, Colombes, France), which includes an oncology unit and a vascular disease unit. She set up a tele-expertise service to help physicians manage patients with anticoagulant concerns. She is also chair of the scientific council for the INNOVTE-FCRIN Network (Investigation Network on Venous Thrombo-Embolism) and for a patient association taking anticoagulant (Anticoag PASS S2D). She has broad experience in methodology and in clinical trials evaluating anticoagulants in different cardiologic or vascular settings. Her own research projects have resulted in a better management of anticoagulants in complex patients (renally impaired, elderly and cancer patients). She is leading the international prospective randomised API-CAT Study (focusing on the extended anticoagulant treatment in patients with cancer-associated thrombosis).

#### **Kieron Power, Lead Pharmacist, Swansea Bay University Health Board**



Kieron is the principal pharmacist for thrombosis and anticoagulation at Swansea Bay University Health Board in South Wales. He is the lead clinician for the ambulatory VTE and CAT service. He is also the clinical lead for thrombosis and anticoagulation within his health board. Kieron's primary interests have been based around improving the experience for patient undergoing treatment of CAT and supporting pharmacists in undertaking clinical roles within the spectrum of VTE and CAT. Kieron sits on the UK Clinical Pharmacy Association Thrombosis Committee.

**Nick van Es, Internist Vascular Medicine, Amsterdam University Medical Centre**



Nick van Es is an internist specialized in Vascular Medicine at the Amsterdam University Medical Center. He defended his PhD-thesis “Cancer and thrombosis: improvements in strategies for prediction, diagnosis, and treatment” cum laude in 2017 supervised by Prof. Saskia Middeldorp and Prof. Patrick Bossuyt. He was a research trainee at the Ottawa Hospital supervised by Prof. Marc Carrier and was trained as a Clinical Epidemiologist by Prof. Patrick Bossuyt. His current research focuses on prediction, diagnosis, and treatment of venous thromboembolism, with a particular interest in cancer-associated thrombosis. He has co-authored about 90 peer-reviewed publications and has established collaborations with various national and international experts in the field.

**Anthony Maraveyas, Professor in Cancer Medicine, Hull University Teaching Hospitals NHS Trust & Hull York Medical School**



Professor Anthony Maraveyas is professor of Cancer Medicine at Hull York Medical School. He was appointed by the University of Hull in 1999 as part of the Post Graduate Medical School foundation team that led to the establishment of the Hull York Medical School (HYMS) in 2003. He is currently director of the HYMS Clinical Sciences Centre (CSC) having previously been the director of R&D for Hull University teaching Hospitals NHS Trust (HUTH).

In his clinical role, he treats patients with pancreatic cancer, melanoma and renal cell carcinoma and leads the Cancer Trials Unit at Castle Hill Hospital.

Amongst his clinical research activity, he has been national chief investigator for a number of studies in cancer-associated thrombosis (CAT). He has published widely in this field with particular focus on the thromboprophylaxis of the ambulant cancer patient and the management of incidental pulmonary embolism in cancer patients. He has been Co-Chair of the Cancer and Thrombosis Scientific and Standardisation Committee (SSC) of the International Society in Thrombosis and Haemostasis (ISTH).

He has been involved in cancer associated guideline bodies [such as the British Society of Haematology (BSH) and European Society of Medical Oncology (ESMO)].

**Miriam Johnson, Professor Palliative Medicine, Hull York Medical School**



Miriam Johnson (MD; MRCP, MB ChB (Hons)) is Professor of Palliative Medicine at Hull York Medical School, Associate Director of the Wolfson Palliative Care Research Centre at the University of Hull, and Adjunct Professor at the University of Technology, Sydney, Australia. Her interests include i) management of venous thromboembolism in advanced cancer and mechanisms and ii) management of breathlessness and inequalities in palliative care service provision e.g., for people with non-malignant disease such as heart failure and respiratory disease. For 20 years she was also a consultant palliative physician.